Pharma — Februar 2023
-
Sandoz: FDA To Review BLA For Proposed Biosimilar Denosumab https://www.proinvestor.com/investornyt/936717/sandoz-fda-to-review-bla-for-proposed-biosimilar-denosumab
-
ALK-Abelló får lagt en tier oven i kursmålet hos Danske Bank https://www.proinvestor.com/investornyt/936732/alk-abello-far-lagt-en-tier-oven-i-kursmalet-hos-danske-bank
-
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly https://www.proinvestor.com/investornyt/936862/johnson-amp-johnsons-latest-talcum-powder-development-could-be-costly
-
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock? https://www.proinvestor.com/investornyt/936866/could-this-indication-provide-a-lift-for-bristol-myers-squibbs-stock
-
AstraZeneca: European Commission Approves Forxiga In Treatment Of Symptomatic Chronic Heart Failure https://www.proinvestor.com/investornyt/937342/astrazeneca-european-commission-approves-forxiga-in-treatment-of-symptomatic-chronic-heart-failure
-
Roche Announces Positive Results From Phase III Study Of Crovalimab In PNH https://www.proinvestor.com/investornyt/937336/roche-announces-positive-results-from-phase-iii-study-of-crovalimab-in-pnh
-
ALK-Abelló får hævet kursmålet til 130 kr. fra 120 kr. hos Danske Bank https://www.proinvestor.com/investornyt/937349/alk-abello-far-haevet-kursmalet-til-130-kr-fra-120-kr-hos-danske-bank
-
Lundbeck nedskriver på Vyepti-lagre og giver 2023-prognose https://www.proinvestor.com/investornyt/937422/lundbeck-nedskriver-pa-vyepti-lagre-og-giver-2023-prognose
-
Lundbecks indtjening slår forventningerne i markedet https://www.proinvestor.com/investornyt/937443/lundbecks-indtjening-slar-forventningerne-i-markedet
-
Why Amgen is a Top 25 Dividend Giant (AMGN) https://www.proinvestor.com/investornyt/937444/why-amgen-is-a-top-25-dividend-giant-amgn
-
Lundbecks kurshop skyldes til dels
annullering af shorts https://www.proinvestor.com/investornyt/937507/lundbecks-kurshop-skyldes-til-dels-annullering-af-shorts -
Lundbeck-topchef bruger langsigtet mål til at understrege tro på vækst https://www.proinvestor.com/investornyt/938048/lundbeck-topchef-bruger-langsigtet-mal-til-at-understrege-tro-pa-vaekst
-
Pharma og biotek - opdatering fra debat og chat uge 6 Ambu ' Lundbeck ' ALK-Abelló ' ChemoMetec
Helge Larsen kommenterer de seneste regnskaber fra virksomheder inden for pharma og biotek ud fra den kvalificerede debat og chat på proinvestor.com Kort video https://www.proinvestor.com/boards/110334
-
Lundbeck/Sydbank: Toppen af prognosen er inden for rækkevidde https://www.proinvestor.com/investornyt/940501/lundbeck-sydbank-toppen-af-prognosen-er-inden-for-raekkevidde
-
Britisk storbank løfter kursmål for Lundbeck og gentager
"outperform"https://www.proinvestor.com/investornyt/943022/britisk-storbank-lofter-kursmal-for-lundbeck-og-gentager-outperform -
Teva's AUSTEDO XR Receives FDA
Approval For Movement Disorders Treatment https://www.proinvestor.com/investornyt/943498/tevas-austedo-xr-receives-fda-approval-for-movement-disorders-treatment
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind